Big Win In India s Fight Against Covid-19: Covishield Vaccine Gets Conditional Approval
SII s Covishield vaccine (Pic Via Twitter)
The 10-member Subject Expert Committee (SEC) of India s Central Drug Standard Control Organisation (CDSCO) today (1 January) approved emergency use authorisation of the Oxford-AstraZeneca coronavirus vaccine Covishield .
As per reports the SEC recommended in favour of the emergency use authorisation to the DCGI subject to certain conditions. The vaccine has been developed by scientists at the UK s Oxford University and is produced by AstraZeneca.
The expert panel had convened a meeting to take a call on the emergency use authorisation sought by the Serum Institute of India, the manufacturer of Covishield, and Bharat Biotech for its Covaxin.
: Friday, January 1, 2021, 7:39 PM IST
Govt will bear cost of vaccinating 30 crore individuals, not the entire population: COVID-19 task force head Dr Vinod Paul
The Central government has finally approved emergency use authorisation of the Oxford-AstraZeneca s coronavirus vaccine Covishield .
Only 30 crore people to be vaccinated, not the entire population: COVID-19 task force head Dr Vinod Paul
Photo Credit: PTI
India s COVID-19 task force head and NITI Aayog member, Dr Vinod Paul, on Friday said that the government with bear the cost of vaccinating 300 million (30 crore) individuals. These individuals will be from the priority groups as identified by the government and not the entire population. Notably, frontline workers, healthcare workers and the elderly will be among those targeted in the initial phase of vaccination.